Pfizer, BioNTech report high 95% efficacy of booster shot from trial
#1

Pfizer and its German partner BioNTech yesterday said that data from a Phase III trial demonstrated high efficacy of a booster dose of their Covid-19 vaccine against the virus, including the Delta variant.

They said a trial of 10,000 participants aged 16 or older showed 95.6 per cent effectiveness against the diseases, during a period when the Delta strain was prevalent.

The study also found that the booster shot had a favorable safety profile....

Part of an article found in today's The New Paper
Reply


Messages In This Thread

Forum Jump:


Users browsing this thread: 1 Guest(s)